Related Experiment Video
Updated: Aug 1, 2025
11:18
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
16.1K
Dasatinib-Induced Chylothorax: A Clinical Laboratory's Perspective
Rafael J García Martínez1,2, Clara Sanz Gea3, Víctor Martin-Riera3
1Clinical Analysis Department, Marqués de Valdecilla University Hospital, Santander, Spain.
EJIFCC
|May 1, 2023
Summary
Dasatinib, a leukemia drug, can rarely cause chylothorax, a condition affecting the chest cavity. This case highlights the importance of laboratory tests in diagnosing this rare side effect in long-term patients.
Area of Science:
- Oncology
- Pharmacology
- Pulmonology
Background:
- Dasatinib is a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML).
- Chylothorax is a rare, poorly understood side effect of long-term dasatinib therapy.
- Diagnosis of chylothorax relies on laboratory analysis of pleural effusion.
Observation:
- A 53-year-old male patient developed chylothorax.
- The patient had a 14-year history of dasatinib treatment for CML.
- Clinical laboratory analysis was instrumental in diagnosing the chylothorax.
Findings:
- The case report details a rare instance of chylothorax in a patient undergoing long-term dasatinib treatment.
- Laboratory findings confirmed the presence of chylothorax.
- The pathophysiology of dasatinib-induced chylothorax remains unclear.
Implications:
- This case underscores the importance of considering chylothorax as a potential complication in patients on long-term dasatinib.
- Clinical laboratory analysis is essential for accurate and timely diagnosis.
- Further research into the pathophysiology of this rare side effect is warranted.
